BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Eli Lilly Stock Plunges Despite Strong Q2 Results Due to Orforglipron Concerns
Eli Lilly Stock Plunges Despite Strong Q2 Results Due to Orforglipron Concerns
15
2
BTCCSquare news:
Eli Lilly's shares tumbled 14.8% despite reporting better-than-expected Q2 2025 earnings, driven by strong sales of Mounjaro and Zepbound. The decline followed mixed results from a Phase 3 trial of oral GLP-1 agonist orforglipron, which showed 12.4% average weight loss but fell short of some Wall Street expectations.
Investors reacted sharply to the 10.3% discontinuation rate in the high-dose group, overshadowing CEO Dave Ricks' Optimism about the drug's commercial potential. The market's punitive response highlights the intense scrutiny facing weight-loss therapies in competitive development pipelines.
By:
